VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 441.00 thousand shares for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2015-02-13
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2014 was 441.00K shares, a 43.46% decline from fiscal 2013.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2013 was 780.00K shares, a 200.00% increase from fiscal 2012.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2012 was 260.00K shares, a 3.35% decline from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2011 was 269.00K shares, a 174.49% increase from fiscal 2010.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|
| 2014-12-31 | 441.00K shares 10-K · filed 2015-02-13 |
| 2013-12-31 | 780.00K shares 10-K · filed 2014-02-11 |
| 2012-12-31 | 260.00K shares 10-K · filed 2013-03-01 |
| 2011-12-31 | 269.00K shares 10-K · filed 2012-02-22 |
| 2010-12-31 | 98.00K shares 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |